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The high extent of misuse of synthetic anabolic androgenic steroids (AAS) in sports by athletes to improve their physical performance became public in the 1970s.' The International Olympic Committee (JOG) in 1974 banned the use of synthetic AAS by athletes.
This prohibition was also adopted by all national and international sports federations. This ban encouraged drug testing laboratories to develop methods for the detection of misused anabolic steroids. The first methods, based on radioimmunoassay techniques [1, 2] , failed to take into account the high extent of metabolism of AAS. For detecting and identifying AAS metabolites, gas chromatography-mass spectrometry (GC-MS) is the current method of choice [3] [4] [5] . Because most AAS are extensively metabolized and the parent steroids are detected for only a short period after administration, the detection of AAS metabolites allows one to confirm the misuse of AAS for a longer time. To follow this strategy, investigators must determine the metabolism of anabolic steroids in humans, elucidate the structures of the metabolites, and, if possible, synthesize the metabolites for use as reference materials. This has been done over the past years for the main metabolites of those AAS that are the most frequently misused [6] .
Confirmation of AAS misuse is based on comparison of the electron impact (El) mass spectrum, or selected ion profile, and GG retention time of the trimethylsilyl (TMS) derivatives of the steroid and (or) its metabolite (s) with the corresponding data obtained from synthesized reference substances [6] or from characterized reference substances (e.g., metabolites) isolated from urine in an excretion study.
In 1984 the use of testosterone was also banned by the lOG and by all other sports federations.
A method for the detection of administered testosterone was developed by Donike et al. [7] in 1983, in which the ratio of urinary excreted testosterone glucuronide to epitestosterone glucuronide was used as an indicator for testosterone administration. The following discussion on the metabolism of anabolic steroids is based mainly on published results from various working groups and from my own group's published and unpublished investigations. All investigations were performed as urinary excretion studies with male subjects. The studies followed the ethical agreement of the University. All studies in our laboratory were based on self-administration of a single oral dose of an anabolic steroid. The identification of metabolites was confirmed by GC-MS. Several metabolites were synthesized to confirm their structures, and in several cases conformation was based on comparison with structurally related steroids. Characteristic fragment ions of AAS as TMS derivatives in their El mass spectrum were used to confirm the proposed structures. Chemical reactions and enzymatically catalyzed conversions of functional groups were also used as evidence for their structures.
Testosterone andSynthetic MS

Testosterone
( Fig. 1) is the principal androgenic steroid and is produced in males mainly in the testis. In females, smaller amounts of testosterone are produced by the ovary and the adrenal gland. Testosterone was first discovered in 1935 by David et al. [8] , who isolated it from the testis of bulls but did not identify its structure. The structure elucidation by synthesis was performed in the same year independently by Butenandt and Hanisch [9] and Ruzicka and Wettstein [10] . For this work Butenandt and Ruzicka were awarded the Nobel prize in 1939. Interest in testosterone, which possesses anaholic and andro- 5a-isomer metabolism: 5a-and 513-reductionof 3-keto-4-ene
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Schanzer: Metabolism of anabolic androgenic steroids reviewed genic properties, is based on its ability to stimulate anabolic activities. In medical treatment the use of testosterone improves recovery from catabolic states. Soon after testosterone was identified, it was seen to be not effective when given orally or by parenteral injection, being very rapidly absorbed to the portal blood system and metabolized in the liver. To circumvent this first-pass effect, users administer testosterone as an ester or chemically modified (synthetic AAS). Because of the anabolic and androgenic effects of testosterone, investigators have also wanted to synthesize AAS that have more anabolic and less androgenic activity than testosterone. The first synthetic anabolic steroids were methyltestosterone, mestanolone, and methandriol, all synthesized by Ruzicka et al. in 1935 [11] . In all these steroids, a methyl group is introduced at position C-17a, which makes the 17a-methyl steroids orally effective by slowing their metabolism. The 17 a-methyl group is not removed and inactivation occurs only after alteration of the A-ring. The importance of the therapeutic use of AAS in treatment of catabolic conditions was recognized in the 1950s, after which an enormous number of steroids were synthesized and tested for potency. For example, metandienone [12, 13] and stanozolol [14, 15] , two of the most frequently misused AAS, were synthesized in 1955 and 1959, respectively. Besides l7a-methylation, further modifications were made to reduce the rate of metabolic inactivation. Alteration of the A-ring by introduction of a double bond at G-l,2 yielded metandienone.
In stanozolol, a pyrazol ring was condensed to the A-ring, which greatly slowed the rate of metabolic transformation. The metabolism of testosterone can be discussed as a basic metabolic pathway for all synthetic AAS. The enzymes that convert testosterone to its distinct metabolites are also active towards AAS when similar groups and configurations are present. The metabolism of testosterone has been investigated in various tissues in vivo and in vitro in several animal models and in clinical studies in humans [16] [17] [18] [19] [20] . Several of these studies were performed with ['4G}testosterone to identify possible testosterone metabolites unambiguously.
Overviews on the high number of metabolites have been published [21, 22] . The main excreted testosterone metabolites 3 a-hydroxy-5 a-androstan-17-one (androsterone), 3 a-hydroxy-5 j3-androstan-17-one (etiocholanolone), 3f3-hydroxy-5 a-androstan-17-one (epiandrosterone), 5a-androstane-3 a, 1713-diol, 5f3-androstane-3 a, 17f3-diol, and 5ts-androstane-3f3,17f3-diol are detected in routine urine samples for drug testing and are part of the so-called steroid profiling.
These most abundant metabolites are produced by oxidoreductive reactions at C-3, C-4, C-5, and C-17. Hydroxylated metabolites generated by different isoenzymes of 5a-reductase / \ 5&-reductase 44 51 !-isomer cytochrome P-450 are not discussed here because their excretion into human urine is extremely low.
General Metabolism of MS
The following overview is a systematic discussion of metabolic changes in the steroid molecule according to the regions (A-D rings; Fig. 1 ) of the perhydrocyclopentanophenanthrene ring system, the basic structure of all steroids. These changes are generally grouped into two kinds of metabolism, phase I and phase II, the latter also being referred to as conjugation of the steroid.
Phase I Metabolism
Phase I reactions usually convert the steroid by enzymatically catalyzed reactions (e.g., oxidation, reduction, or hydroxylation) into more polar compounds to inactivate the drug and to facilitate its elimination from the body.
A-RING METABOLISM
5a-and 5(3-reduction. The initial and rate-limiting step in the metabolism of 3 -keto-4-ene steroids, such as testosterone, is the reduction of the C-4,5 double bond. The reduction yields an asymmetric center at C-5, such that two isomers with 5a-(hydrogen at C-S below the planar molecule) and 513-configuration (hydrogen at C-5 above the planar molecule) can be formed (Fig. 2) . The enzymes catalyzing the reactions, 5a-reductase and 513-reductase, are located mainly in the liver [23] -5a-reductase primarily in the endoplasmic reticulum and 5(3-reductase in the cytoplasm. Both enzymes require NADPH as a cofactor [24] . Once the double bond is reduced, the 3-keto group is immediately transformed, as discussed later. Hydrogenation of the G-4,5 double bond of metandienone and some structurally related A-ring substituents after reduction of the 3-keto group was discussed by Masse et al. [25] . Table 1 summarizes the proposed and observed reduction to Sa-and 5(3-isomers for all discussed 3-keto-4-ene AAS. The extent of 5a-and Sf3-isomer produced depends on the structure of the steroid, as Table 2 summarizes for the metabolism of AAS in one male individual. 3 -Keto-androsta-1,4-diene structures, such as metandienone and boldenone, do not produce 5a-isomers [26] [27] [28] . Differences in the D-ring structure also strongly influence the activity of both enzymes. As shown in (Fig. 4 , left) has been reported for metandienone [26] . An excretion study with orally applied 17a-methyl-5/3-androstl-ene-3a,1713-diol [26] showed that the C-l,2 double bond was [37], and metenolone [38] . See also the specific sections on these compounds presented later.
B-RING METABOLISM
613-Hydroxylation.
Metabolism of the B-ring is most pronounced for 1713-hydroxy-17 a-methyl steroids where A-ring reduction is hampered by the presence of a C-1,2 double bond, e.g., in metandienone and 4-chlor-I ,2-dehydro-17a-methyltestosterone, and by the C-9a fluorine atom in fluoxymesterone.
Hydroxylation at position C-6f3 is the main metabolic route in these anabolic steroids (Fig. 5 ) [39] [40] [41] . Excretion studies have not detected any oa-hydroxy metabolites.
6, 7-Dehydrogenation. 6,7-Dehydrogenation is a minor metabolic pathway, observed only in the metabolism of metandienone [42] . The generation of this metabolite is proposed to originate from an unknown conjugate.
In an excretion study with metandienone, the 6,7-dehydro metabolite was obtained after diethyl ether extraction of the alkalinized (pH >12) urine but not at pH 7.0. This conjugate was isolated from urine via fractionation from an Amberlite resin (XAD-2) (Sch#{228}nzer and Donike, unpublished data, 1988-93; see also Conjugation at the B-ring). When the isolated fractions were alkalinized (pI-I >12), the 6,7-ene metabolite was obtained.
These results can be explained with a basic labile conjugate possibly conjugated at C-6 or C-7, which generates a 6,7-ene when cleaved. A 6,7-dehydro product of testosterone has also been reported in incubation experiments of liver homogenates of rats with testosterone [43] . 
C-RING METABOLISM: I 2-HYDROXYLATION
Metabolic changes of anabolic steroids at the C-ring are modest. 12-Hydroxylation was first proposed by D#{252}rbeck et al. [44] for the metabolism of 4-chlor-l ,2-dehydro-1 7a-methyltestosterone. The proposed 12-hydroxylation of metandienone, stanozolol [26, 34] , and 4-chlor-1,2 -dehydro-17a-methyltestosterone could be confirmed [6] . The TMS derivatives of these metabolites show ion fragments at m/z 143 and 170. The ion m/z 170 was detected in a synthesized 12-hydroxylated l7f3-hydroxv17a-methyl steroid [26] . The ion m/z 143 is the typical D-ring fragment of TMS derivatives of 17f3-hydroxy-17a-methyl steroids, whereas m/z 170 is a C-D-ring fragment and occurs after hydroxylation at C-l2. The stereochemistry at C-l2 (C-12a or C-12f3) is not known. 16a-and 1613-hydroxylation. Hydroxylation at C-l6a and C-16[3 has been reported for several anabolic steroids [6, 26, 34, 44, [47] [48] [49] . 16-Hydroxylation is well described in the metabolism of estrogens [50] . Stereospecific hydroxylations are observed at C-16a and C-16f3 (Fig. 6, bottom) , but the extent of formation of both isomers differs for different AAS. There is no general rule, and in some cases only one isomer is excreted. The exact elucidation of the isomers is not always performed.
D-RING METABOLISM
17-Oxidation
In the metabolism study of stanozolol [34] , the possible four isomers with the 16,17-dihydroxy-l7-methyl structure were synthesized, and their GC retention indices (determined as per-TMS derivatives) showed the following order: 1613-hydroxy-17-epistanozolol < 16a-hydroxy-l7-epistanozolol < loa-hydroxy-stanozolol < 16(3-hydroxystanozolol. hydroxy configuration (see 3a-and 3-13 reduction). The 3a-hydroxy steroids are conjugated with glucuronic acid (Fig. 7 ) regardless of whether the steroid has a Sa-or 5/3-configuration [54] . 313-Hydroxy steroids, on the other hand, are excreted as sulfates [54] . 3a-O-/3-Glucuromdes are the major metabolites of AAS; however, some androgens are excreted also as sulfates, e.g., androsterone, etiocholanolone, epiandrosterone (major metabolite excreted), testosterone, and epitestosterone.
Conjugation at the B-ring.
Conjugation of steroids at the B-ring has not been published. In the metabolism of metandienone, the 613-hydroxymetandienone is excreted mainly as a labile conjugate (Sch#{228}nzer and Donike, unpublished data, 1988-93). The conjugate, which could be isolated from urine by use of HPLC, was stable at pH 3-8 but hydrolyzed spontaneously in alkaline aqueous solution to yield 6/3-hydroxymetandienone.
The conjugate also hydrolyzed in urine after several days when stored at 4 #{176}C. The nature of this conjugate has not been established yet. Another unknown B-ring conjugate, which is converted to a 6,7-dehydro metabolite of metandienone, was discussed above (see 6, 7-Dehydrogenation).
Conjugation at the D-ring.
1) Glucuronidation of the secondary 17/3-hydroxy group. Glucuronidation at the 17(3-hydroxy group in secondary 17/3-hydroxy steroids (Fig. 8, left) is well known for testosterone. AAS with secondary 17(3-hydroxy groups such as methenolone, mesterolone, drostanolone, and clostebol are excreted as conjugates that are readily hydrolyzed with (3-glucuronidase from Escherichia coli. This enzyme (used throughout, unless otherwise specified) is highly specific for hydrolysis of (3-glucuronides of alcoholic groups, especially in steroids. The specificity of this enzymatic hydrolysis allows us to assume that these conjugated steroids are excreted as 1713-glucuronides.
Experiments to determine the configuration of these conjugates are in progress. and could be detected for a longer time after ingestion than the parent steroid. The structure of both metabolites was confirmed by synthesis of the authentic standards [6, 58] . [28] . The main metabolic routes in boldenone metabolism are shown in Fig. 11 . Boldenone itself is excreted as a 17(3-conjugate, presumably as a I 7/3-glucuronide because of its specific hydrolysis with (3-glucuronidase.
2)
The reduction of the C-4,5-double bond is stereospecific and yields the 5/3-configuration. No 5cs-metabolite is detected. The main metabolites of boldenone are I 7(3-hydroxy-5(3-androst-1-en-3-one (2), 5(3-androst-I -ene-3 a, I 7f3-diol (4), and 3 a-hydroxy-5(3-androst-1- en-l 7-one (6). 6/3-Hydroxylated metabolites are also excreted but only to a low extent [28] . Excretion 2), but also a 5a-metabolite (7/3,17a-dimethyl-5a-androstane-3a,17(3-diol; 3 in Fig. 12 ). The ratio of the 5/3-to 5a-metabolite was -4:l (Table 2) . We also identified excretion of a 17-epimeric tetrahydro metabolite, 4 (fully A-ring reduced), present at -10% of the concentration of the 5/3-tetrahydro metabolite.
4-CHLORO-1,2 -DEHYDRO-I 7a-METHYLTESTOSTERONE
The anabolic steroid 4-chloro-1,2-dehydro17a-methyltestosterone ( Fig. 13) [6, 41] . Two additional metabolites identified from excretion studies, the 6(3,1613-dihydroxy (3) and 6/3,1 2-dihydroxy [4] forms, are also used to screen for 4-chloro-1,2 -dehydro-17a-methyltestosterone in urine samples of athletes [6] .
A recent reinvestigation of the metabolism of 4-chloro-1,2-dehydro-I 7a-methyltestosterone has found that several metabolites are excreted for a long time after administration [51] . (Fig. 14) . The main metabolite excreted is 4-chloro-3 a-hydroxyandrost-4-en-17-one (2) , which has been synthesized as a reference material [6] . A further abundant hydroxy metabolite (7), hydroxylated at C-b and fully A-ring-reduced, was detected and confirmed by GC-MS. The configuration at C-b and of the A-ring is still unknown. Besides these metabolites, which are all excreted as glucuronides, a 17-keto tetrahydro metabolite has been isolated as a sulfate conjugate.
This metabolite has the most prolonged detection time after administration of clostebol. Because the A-ring is fully reduced and the metabolite is excreted as a sulfute, we propose the configuration 4-chloro-3/3-hydroxy-5a-androstan-i 7-one (6) . The configuration at C-4 (bearing the chloride ion) is still unclear.
The exact clarification of the A-ring (1 7/3-hydroxy-2 a-methyl-5a-androstan-3 -one; Fig. 15 analog. This metabolite has been synthesized as a reference substance [6] . Possible reaction pathways for genera- Proposed structures for metabolites 4-7: 4, 4-chloro3a-tiydroxy-5a-androstan-17-one; 5, 4chloro-3a-hydroxy-51.3-androstan-17-one; 6, 4-chloro-3(3-hydroxy-5a-androstan-17-one;
7, 4f-chloro-3a,16f-dihydroxy-5f-androstan-17-one.
tion of this metabolite are shown in Fig. 15 . A minor metabolite, 2a-methyl-5a-androstane-3a,17/3-diol (3), is also formed. to be due to the presence of the 11 /3-hydroxy group in flu- 
ETHYLESTRENOL
FORMEBOLONE
Formebolone (2-formyl-11 a, I 7/3-dihydroxy-I 7a-methylandrosta-l,4-diene-3-one; Fig. 18 , left) was synthesized in 1965 by Canonica et al. [72] . GC-MS investigation of formebolone metabolism in humans was published by Masse et al. [37] in 1991, who proposed metabolite structures as related to their El mass spectra.
To confirm the structure of the primary metabolite, Donike and I performed an excretion study with 20 mg of formobolone taken orally [6] . A reduced metabolite, 2-hydroxymethyl-11 a, 17/3-dihydroxy17a-methylandrosta-1,4-diene-3-one (2; Fig. 18, left) , was found in the unconjugated urine fraction after basic extraction and was identified by comparison with the synthesized compound [6] . showed that furazabol was excreted as a conjugate that could be hydrolyzed with /3-glucuronidase. From this result it is assumed that furazabol is excreted as a l7/3-glucuronide. Further work to confirm this assumption is in progress. A 16-hydroxy metabolite was also identified, although its exact configuration (1 6a-hydroxy or 16(3-hydroxy) is still not determined.
16-Hydroxy metabolites of
17-hydroxy-17-methyl steroids can be easily confirmed by CC-MS from the characteristic El mass spectra for D-ring fragment ions from the TMS derivative [26, 34] .
MESTANOLONE
Mestanolone
(1 7/3-hydroxy-17a-methyl-5a-androstan-3-one)
was first synthesized in 1935 by Ruzicka et al. [11] . Masse et al. [25] published in 1991 a GC-MS investigation of the mestanolone metabolic pathway (Fig. 19) . After oral administration to a male volunteer, 17a-methyl-5a-androstane-3a,17/3-diol (2) (1) to la-methyl-5a-androstane3a,17J3-diol (2); la-methyl-5a-androstane-3,17-dione (3; not excreted into urine); and 3a-hydroxy-la-methyl-5a-androstan-17-one
(4).
HO'#{149} Sch#{228}nzer: Metabolism of anabolic androgenic steroids reviewed
In 1991, we reported identification of the conjugated A-ring- was excreted as a main conjugate, which can be hydrolyzed with /3-glucuronidase. Mestanolone is rapidly reduced by 3a-hydrox-
This result is in agreement with the metabolism of methyltestosterone, in which, as an intermediate after 5 a-reduction, mestanolone is produced and is further reduced to the corresponding 3a-hydroxy-5a-androstane product. No parent drug nor 3/3-hydroxy metabolites were observed.
Recent experiments (Sch#{228}nzer and Horning, unpublished) have shown that initially a 17-epimer [17/3-methyl-5a-androstane-3 a, 17a-diol (3)] and 18-nor-17,1 7-dimethyl-5 a-androst-13-en-3a-ol (4) are excreted in low amounts (1-2% of the main metabolite), both as conjugates (3a-hydroxy glucuronides). This excretion pattern changes after several days. After 14 days, for example, all metabolites were excreted in comparable low amounts. Even later, after as long as 21 days, the excretion of the epimer exceeds the excretion of the main metabolite. The formation of the epimer follows the epimerization process already described via a 17/3-sulfate, and the excretion of the l8-nor-17,17-dimethyl product is in agreement with this mechanism. Because all these metabolites have a 3a-hydroxy structure, they are conjugated with glucuronic acid before excretion into urine. The excreted sulfate is therefore a bis-conjugate and, Fig. 19 . Metabolism of mestanolone (1) to 17a-methyl-5a-androstane3a,17/3-diol (2); 17a-methyl-5a-androstane-3a,17/3-diol 17/3-sulfate (3); 18-nor-17,17-dimethyl-5a-androst-13-en-3a-ol (4) ; and 17/3-methyl-5a-androstane-3a,17a-diol (5).
after the rearrangement process, the formed products are still conjugated (3 a-hydroxy conjugate).
MESTEROLONE
Mesterolone (17(3-hydroxy-la-methyl-5a-androstan-3-one) was synthesized by Wiechert in 1965 [76] . Human metabolism of mesterolone was reported by DeBoer et al. [31] and Goudreault and Ayotte [32] . Masse and Goudreault reported 18-hydroxylation as a minor metabolic pathway of mesterolone [53] . DeBoer confirmed by GC-MS the urinary excretion of the parent steroid (conjugate, hydrolysis with /3-glucuronidase), la-methyl-S a-androstane-3 a, I 7/3-diol (2) and the androsterone analog (4) as major metabolites (Fig. 20) . This metabolite was further elucidated by synthesis [6] as 3a-hydroxy-la-methylSa-androstan-17-one (4).
METANDIENONE
Metandienone (l7/3-hydroxy-17a-methylandrosta-1,4-dien-3-one; Fig. 21 Rongone and Segaloff [39] . This metabolite was excreted unconjugated.
As discussed above (Conjugation at the B-ring), recent experiments have shown that 6/3-hydroxymetandienone is mainly excreted as a labile conjugate, the structure of which is unknown. A further metabolite, 17-epimetandienone (5), was identified and synthesized in 1971 by Macdonald et al. [77] . As reported later [58, 60] , the 17-epimeric product results from degradation and rearrangement of an excreted 17/3-sulfate. Further publications [42, 44] present results from GC-MS investigations of the unconjugated fraction. reduced metabolites [26] . These include (Fig. 21 ): 17/3-methyl-5(3-androst-1-ene-3a, 17a-diol (7), 17a-methyl-5/3-androst-l-ene3a, 17 (3-diol (9) , and 17a-methyl-5/3-androstane-3a, 17(3-diol (10). The 17-epimer, 7, is a long-term excreted metabolite; it can be detected for a very long time after the administration of metandienone. Because the formation of this 17-epimer is followed by the general degradation process to the corresponding 17/3-sulfate, it is also possible to detect the 18-nor product, 18-nor-l 7,1 7-dimethyl-5/3-androsta-1,1 3-dien-3a-ol (8) .
METHENOLONE
Methenolone (17(3-hydroxy-1-methyl-5a-androstan-3-one; Fig. 22 (2) and 17a-methyl-5/3-androstane-3a,17f3-diol (3).
MIBOLERONE
Mibolerone
(1 7/3-hydroxy-7a, 17a-dimethylestr-4-en-3 -one) was synthesized in 1963 by Segaloff [81] . The metabolism of mibolerone was investigated by Bowers [82] and after oral application of 20 mg to a male volunteer (Geyer, Sch#{228}nzer, Donike, unpublished).
A major excreted product was the fully A-ring-reduced metabolite, which was excreted as a conjugate. The structure of this metabolite is assumed to be 7a,17a-dimethyl-5/3-estrane-3a,17(3-diol (2; Fig. 23, right) ; however, this has not yet been confirmed.
The proposed structure is in agreement with the reduction of mibolerone in methanol! potassium hydroxide by hydrogen, with platinum dioxide as a catalyst; the reduction yields only one intermediate with 3 -keto structure.
The 5(3-configuration is based on hydrogenation results for the structurally related steroid bolasterone (Fig. 10) , which yields only a 5/3-product under the same conditions. The 3a-hydroxy structure is in agreement with the hydrolysis of the conjugate (glucuronide) with /3-glucuronidase.
NANDROLONE (i 9-NORTE5TOSTERONE)
Nandrolone (17/3-hydroxyestr-4-en-3 -one; Fig. 25 ) was synthesized in 1950 by Birch [83] and by Wilds and Nelson [84] in 1953. The metabolism was investigated by Engel et a!. in 1958 [85] . The metabolism strongly follows that of testosterone, and the main metabolites have been confirmed as 3a-hydroxy-5a-estran-17-one (3, norandrosterone) and 3 a-hydroxy-5 /3-estran-17-one (2, noretiocholanobone).
The structure of both metabolites was elucidated by synthesis in 1960 [86] . Besides these metabolites, a 3 (3-hydroxy isomer, 3 /3-hydroxy-5a-estran-17-one (4) , is also excreted into urine as a 3(3-sulfate in an amount similar to that of the 3 a-hydroxy metabolites (Sch#{228}nzer and Donike, unpublished data, 1988-93) .
NORCLOSTEBOL
Norclostebol (4-chloro-17(3-hydroxyestr-4-en-3 -one; Fig. 26 ) was first synthesized by Camerino et a!. [63, 87] . We investigated its metabolism after a single oral dose of 20 mg of norciostebol acetate to a male volunteer (Geyer, Donike, Sch#{228}n-zer, unpublished).
Only the glucuronide fraction (hydrolyzable (1) to 3a-hydroxy-5/3-estran-17-one (2), 3a-hydroxy-5a-estran-17-one (3), and 3j3-hydroxy-5a-estran-17-one (4) .
with /3-glucuronidase) has been analyzed. The four metabolites we detected are in agreement with the metabolism of clostebol (see above). All metabolites have a 17-keto group; two (4, 5) are fully A-ring-reduced metabolites (possible androsterone and etiocholanolone analogs); one has a 3 -hydroxy-4-ene structure (2); and the fourth is proposed to be C-b hydroxylated (6) . The proposed structures presented in Fig. 26 
OXYMETHOLONE
Oxymetholone
(1 7/3-hydroxy-2 -hydroxymethylene17a-methyl-5a-androstan-3-one) was synthesized in 1959 by Ringo!d et a!. [67] . Its metabolism in humans was discussed by Bi et al.
[ 35, 36] , who identified the urinary excretion of acidic metabolites (Fig. 30 ). They reported a 2-carbonic acidic metabolite (3) and, further, several seco diacetics as metabolites.
In the neutral and basic fractions, several hydroxylated and reduced metabolites were detected, but their structural elucidation was not possible.
A known metabolite I 7a-methyl-5 a-androstane3a,17 (3-diol (4) , which is also a metabolite of methy!testosterone, has been detected. This metabolite originates via oxidation of the 2-hydroxymethylene group to a (3-ketocarbonic acid intermediate (2), which is then decarboxylated to 17(3-hydroxy17a-methyl-5a-androstan-3-one (not shown in Fig. 30 ). This product is subsequently reduced to the 3a-hydroxy metabolite (4).
QUINBOLONE
Quinbolone
[1 7(3-(l -cyclopenten-1-y!oxy)-androsta-1,4-dien-3-one; Fig. 29 , right] is the l7/3-cyc!opentene ether of boldenone and follows the metabolism of boldenone (see above).
STANOZOLOL
Stanozolo! (1 7(3-hydroxy-17a-methy!-5 a-androst-2-eno[3 ,2-cipyrazole; Fig. 31 ) was synthesized in 1959 by Clinton et a!. [14, 15] . Stanozolol is synthesized starting with oxymetholone (see Fig. 30 ), which is condensed with hydrazine to form a pyrazole ring. In 1989 Masse et a!. published a GC-MS method 32 ) and proposed the expected structures.
TRENBOLONE
Trenbolone
(l7f3-hydroxyestra-4,9,1 l-trien-3-one; Fig. 33 ), used as a veterinary product, was synthesized in 1963 by Velluz et a!. [95] . A GC-MS method for detection of trenbolone and its main metabolite 17-epitrenbolone was first presented in l989 and was published in 1991 by DeBoer et a1. [46] . Trenbolone and I 7-epitrenbolone are both excreted as conjugates that can be hydrolyzed with /3-glucuronidase.
From the specific hydrolysis, one can assume that the liberated trenbolone and its 17-epimer are excreted as /3-glucuronides.
It also seems possible that trenbolone and its !7-epimer are additionally excreted as sulfates. This has not yet been confirmed and will be an interesting subject for future research. Conformation of the 17-epimer was based on its GC retention time and the El mass spectra of different derivatives, all of which show an intense cleavage of the 17a-ether (M -HO-R) or ester group (M -HO-CO-R').
Analysis of trenbolone and its 17-epimer by GC-MS can be problematic when derivatized Fig. 32 . Metabolism of stenbolone (1) to 3a-hydroxy-2-methyl-5a-androst-1-en-17-one (2); 3a-hydroxy-2-methyl-5a-androstan-17-one (3); 16-hydroxy-stenbolone (4); 16-hydroxy-2-methyl-5a-androst-1-ene-3,17-dione (5); and 3,16-dihydroxy-2-methyl-5a-androst-1-en-17-one (6). Enolization of the 3-keto group yields a highly reactive compound that can yield several decomposition products under GC analysis. In this case, different derivatives are used.
